EP300 and hepatocellular carcinoma: Our findings showed that VPA treatment heightened the susceptibility of HCC cells to Sorafenib-induced ferroptosis, a phenomenon that was inhibited by concurrent treatment with the p300/CBP inhibitor (Figure S4A).